| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 52 | 2025 | 701 | 10.340 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 23 | 2024 | 142 | 5.380 |
Why?
|
| Antipsychotic Agents | 23 | 2024 | 308 | 4.320 |
Why?
|
| Aged | 218 | 2026 | 15147 | 4.300 |
Why?
|
| Geriatrics | 9 | 2026 | 50 | 4.140 |
Why?
|
| Homes for the Aged | 19 | 2024 | 166 | 4.080 |
Why?
|
| Inappropriate Prescribing | 15 | 2026 | 69 | 3.790 |
Why?
|
| Heart Failure | 34 | 2023 | 968 | 3.610 |
Why?
|
| Anticoagulants | 24 | 2025 | 529 | 3.520 |
Why?
|
| Long-Term Care | 21 | 2021 | 179 | 3.310 |
Why?
|
| Practice Patterns, Physicians' | 26 | 2026 | 712 | 3.180 |
Why?
|
| Aged, 80 and over | 119 | 2026 | 5682 | 3.140 |
Why?
|
| Medication Errors | 20 | 2023 | 127 | 3.050 |
Why?
|
| Dementia | 14 | 2024 | 290 | 3.030 |
Why?
|
| Drug Prescriptions | 18 | 2024 | 165 | 2.870 |
Why?
|
| Humans | 291 | 2026 | 65845 | 2.830 |
Why?
|
| Polypharmacy | 14 | 2024 | 67 | 2.420 |
Why?
|
| United States | 88 | 2025 | 8189 | 2.370 |
Why?
|
| Alzheimer Disease | 6 | 2025 | 774 | 2.370 |
Why?
|
| Patient Selection | 11 | 2021 | 484 | 2.230 |
Why?
|
| Decision Support Systems, Clinical | 10 | 2011 | 76 | 2.210 |
Why?
|
| Male | 184 | 2026 | 31410 | 2.180 |
Why?
|
| Female | 191 | 2026 | 34425 | 2.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2019 | 214 | 2.170 |
Why?
|
| Primary Prevention | 10 | 2019 | 140 | 2.160 |
Why?
|
| Pharmaceutical Preparations | 11 | 2021 | 126 | 2.140 |
Why?
|
| Potentially Inappropriate Medication List | 5 | 2026 | 16 | 2.120 |
Why?
|
| Activities of Daily Living | 6 | 2023 | 294 | 2.030 |
Why?
|
| Myocardial Infarction | 26 | 2021 | 922 | 1.990 |
Why?
|
| Hospitalization | 36 | 2022 | 1404 | 1.930 |
Why?
|
| Accidental Falls | 9 | 2021 | 130 | 1.920 |
Why?
|
| Drug Monitoring | 18 | 2021 | 203 | 1.830 |
Why?
|
| Drug Industry | 5 | 2025 | 41 | 1.830 |
Why?
|
| Atrial Fibrillation | 17 | 2025 | 884 | 1.790 |
Why?
|
| Multiple Chronic Conditions | 6 | 2023 | 40 | 1.750 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 462 | 1.710 |
Why?
|
| Medical Order Entry Systems | 8 | 2011 | 42 | 1.690 |
Why?
|
| Warfarin | 9 | 2025 | 125 | 1.600 |
Why?
|
| Drug Costs | 10 | 2025 | 55 | 1.600 |
Why?
|
| Drug Utilization | 18 | 2020 | 204 | 1.530 |
Why?
|
| Medicare | 13 | 2023 | 629 | 1.490 |
Why?
|
| Chronic Disease | 13 | 2026 | 745 | 1.480 |
Why?
|
| Pharmacists | 3 | 2023 | 131 | 1.470 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2024 | 811 | 1.440 |
Why?
|
| Algorithms | 8 | 2021 | 1060 | 1.420 |
Why?
|
| Patient Discharge | 11 | 2019 | 522 | 1.350 |
Why?
|
| Health Maintenance Organizations | 17 | 2009 | 61 | 1.350 |
Why?
|
| Cohort Studies | 30 | 2025 | 2651 | 1.320 |
Why?
|
| Research Design | 9 | 2023 | 589 | 1.300 |
Why?
|
| Quality of Health Care | 13 | 2016 | 535 | 1.300 |
Why?
|
| Medicare Part D | 9 | 2021 | 36 | 1.240 |
Why?
|
| Retrospective Studies | 56 | 2026 | 6957 | 1.200 |
Why?
|
| Cardiovascular Diseases | 9 | 2017 | 878 | 1.200 |
Why?
|
| Continuity of Patient Care | 4 | 2017 | 175 | 1.180 |
Why?
|
| Databases, Factual | 12 | 2024 | 888 | 1.160 |
Why?
|
| Risk Factors | 52 | 2025 | 5475 | 1.160 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2025 | 146 | 1.140 |
Why?
|
| Electronic Health Records | 6 | 2023 | 398 | 1.130 |
Why?
|
| Marketing | 3 | 2018 | 21 | 1.120 |
Why?
|
| Middle Aged | 90 | 2024 | 18501 | 1.120 |
Why?
|
| Stroke Volume | 9 | 2016 | 346 | 1.110 |
Why?
|
| Medication Systems | 5 | 2021 | 17 | 1.110 |
Why?
|
| Hip Fractures | 6 | 2018 | 79 | 1.110 |
Why?
|
| Patient Readmission | 9 | 2021 | 452 | 1.070 |
Why?
|
| Safety Management | 5 | 2012 | 139 | 1.060 |
Why?
|
| Independent Living | 7 | 2022 | 55 | 1.060 |
Why?
|
| Risk Assessment | 28 | 2022 | 2116 | 1.020 |
Why?
|
| Ambulatory Care | 7 | 2023 | 318 | 1.020 |
Why?
|
| Decision Making | 4 | 2018 | 430 | 0.980 |
Why?
|
| Quality Assurance, Health Care | 5 | 2011 | 253 | 0.960 |
Why?
|
| Geriatricians | 1 | 2026 | 1 | 0.950 |
Why?
|
| Primary Health Care | 6 | 2020 | 726 | 0.940 |
Why?
|
| Atherosclerosis | 2 | 2018 | 162 | 0.930 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 220 | 0.930 |
Why?
|
| Stroke | 13 | 2025 | 1225 | 0.880 |
Why?
|
| Deprescriptions | 2 | 2024 | 29 | 0.870 |
Why?
|
| Obesity | 5 | 2023 | 1281 | 0.870 |
Why?
|
| Body Mass Index | 2 | 2019 | 901 | 0.860 |
Why?
|
| Truth Disclosure | 4 | 2006 | 58 | 0.850 |
Why?
|
| Drug Labeling | 5 | 2013 | 24 | 0.850 |
Why?
|
| Pandemics | 5 | 2022 | 691 | 0.840 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 558 | 0.830 |
Why?
|
| Medical Errors | 5 | 2009 | 202 | 0.820 |
Why?
|
| Surveys and Questionnaires | 18 | 2025 | 2790 | 0.820 |
Why?
|
| Drug Therapy, Computer-Assisted | 3 | 2009 | 13 | 0.810 |
Why?
|
| Evidence-Based Medicine | 5 | 2016 | 464 | 0.810 |
Why?
|
| Endpoint Determination | 2 | 2014 | 27 | 0.800 |
Why?
|
| Family | 2 | 2016 | 250 | 0.780 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 439 | 0.780 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 256 | 0.780 |
Why?
|
| Students, Medical | 2 | 2023 | 270 | 0.780 |
Why?
|
| Physician-Patient Relations | 6 | 2008 | 430 | 0.780 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 318 | 0.770 |
Why?
|
| Defibrillators, Implantable | 8 | 2019 | 276 | 0.750 |
Why?
|
| Frail Elderly | 4 | 2022 | 115 | 0.740 |
Why?
|
| Education, Medical, Undergraduate | 3 | 2015 | 163 | 0.740 |
Why?
|
| Ventricular Function, Left | 8 | 2018 | 284 | 0.730 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 9 | 2011 | 48 | 0.730 |
Why?
|
| Geriatric Assessment | 9 | 2024 | 163 | 0.710 |
Why?
|
| Career Choice | 1 | 2023 | 129 | 0.710 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 19 | 0.710 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1569 | 0.700 |
Why?
|
| Aging | 6 | 2022 | 784 | 0.690 |
Why?
|
| Massachusetts | 23 | 2025 | 2158 | 0.690 |
Why?
|
| Prospective Studies | 15 | 2024 | 3340 | 0.690 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2019 | 171 | 0.680 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2022 | 140 | 0.680 |
Why?
|
| Demography | 3 | 2020 | 178 | 0.670 |
Why?
|
| Research | 3 | 2020 | 195 | 0.670 |
Why?
|
| Antiparkinson Agents | 1 | 2021 | 10 | 0.660 |
Why?
|
| Dopamine Antagonists | 1 | 2021 | 16 | 0.660 |
Why?
|
| Sex Factors | 18 | 2024 | 995 | 0.660 |
Why?
|
| Drug Therapy | 7 | 2008 | 56 | 0.660 |
Why?
|
| Skilled Nursing Facilities | 2 | 2019 | 80 | 0.660 |
Why?
|
| Medical Records Systems, Computerized | 6 | 2009 | 62 | 0.650 |
Why?
|
| Benzoxazoles | 1 | 2020 | 7 | 0.640 |
Why?
|
| Subacute Care | 1 | 2020 | 9 | 0.630 |
Why?
|
| Prevalence | 17 | 2026 | 1454 | 0.630 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2020 | 20 | 0.620 |
Why?
|
| Cognitive Dysfunction | 5 | 2024 | 360 | 0.610 |
Why?
|
| Patient Participation | 2 | 2020 | 239 | 0.610 |
Why?
|
| Biomedical Research | 2 | 2021 | 263 | 0.600 |
Why?
|
| Hemorrhage | 9 | 2025 | 287 | 0.600 |
Why?
|
| Age Factors | 24 | 2024 | 1595 | 0.600 |
Why?
|
| Hypertension | 3 | 2023 | 618 | 0.590 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 413 | 0.580 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2017 | 152 | 0.580 |
Why?
|
| Computer Simulation | 1 | 2021 | 488 | 0.580 |
Why?
|
| Nocturia | 1 | 2018 | 1 | 0.570 |
Why?
|
| Communication | 5 | 2011 | 608 | 0.570 |
Why?
|
| Medical Informatics | 2 | 2016 | 72 | 0.560 |
Why?
|
| Reimbursement, Incentive | 2 | 2009 | 29 | 0.560 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2022 | 63 | 0.550 |
Why?
|
| Renal Insufficiency | 2 | 2009 | 68 | 0.550 |
Why?
|
| Diuretics | 4 | 2023 | 58 | 0.550 |
Why?
|
| Ontario | 11 | 2026 | 58 | 0.540 |
Why?
|
| Prescription Drugs | 6 | 2014 | 49 | 0.540 |
Why?
|
| Multimorbidity | 5 | 2023 | 54 | 0.540 |
Why?
|
| Health Personnel | 2 | 2015 | 391 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 741 | 0.520 |
Why?
|
| Prescription Drug Overuse | 1 | 2017 | 7 | 0.520 |
Why?
|
| United States Food and Drug Administration | 7 | 2014 | 92 | 0.520 |
Why?
|
| Government Regulation | 2 | 2017 | 39 | 0.520 |
Why?
|
| Treatment Outcome | 27 | 2021 | 5834 | 0.510 |
Why?
|
| Incidence | 17 | 2020 | 1433 | 0.510 |
Why?
|
| Adult | 37 | 2024 | 17579 | 0.510 |
Why?
|
| Office Visits | 2 | 2014 | 49 | 0.510 |
Why?
|
| Cross-Sectional Studies | 18 | 2024 | 2739 | 0.510 |
Why?
|
| Time Factors | 25 | 2021 | 3779 | 0.500 |
Why?
|
| Drug Utilization Review | 5 | 2016 | 50 | 0.500 |
Why?
|
| Urinary Catheters | 1 | 2016 | 5 | 0.500 |
Why?
|
| Urethral Obstruction | 1 | 2016 | 6 | 0.490 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2019 | 370 | 0.490 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 20 | 0.490 |
Why?
|
| Frailty | 4 | 2024 | 132 | 0.480 |
Why?
|
| Urinary Retention | 1 | 2016 | 29 | 0.480 |
Why?
|
| Self Report | 2 | 2022 | 395 | 0.480 |
Why?
|
| Societies, Medical | 1 | 2018 | 401 | 0.470 |
Why?
|
| Comorbidity | 10 | 2022 | 1122 | 0.460 |
Why?
|
| Lung Diseases | 1 | 2017 | 183 | 0.460 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 67 | 0.460 |
Why?
|
| Professional-Family Relations | 1 | 2016 | 97 | 0.450 |
Why?
|
| Rationalization | 1 | 2015 | 4 | 0.440 |
Why?
|
| Proportional Hazards Models | 13 | 2018 | 746 | 0.440 |
Why?
|
| Guideline Adherence | 6 | 2013 | 310 | 0.440 |
Why?
|
| Clinical Clerkship | 1 | 2015 | 94 | 0.430 |
Why?
|
| Medication Therapy Management | 2 | 2017 | 18 | 0.430 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2013 | 347 | 0.420 |
Why?
|
| Odds Ratio | 13 | 2021 | 757 | 0.420 |
Why?
|
| International Classification of Diseases | 5 | 2021 | 136 | 0.420 |
Why?
|
| Patient Satisfaction | 5 | 2022 | 442 | 0.420 |
Why?
|
| Reminder Systems | 3 | 2017 | 75 | 0.420 |
Why?
|
| Patient Admission | 1 | 2016 | 200 | 0.420 |
Why?
|
| Connecticut | 6 | 2015 | 90 | 0.410 |
Why?
|
| Caregivers | 4 | 2024 | 298 | 0.410 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 532 | 0.410 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 2500 | 0.410 |
Why?
|
| Anemia | 3 | 2020 | 132 | 0.410 |
Why?
|
| Chi-Square Distribution | 10 | 2017 | 413 | 0.410 |
Why?
|
| Benzodiazepines | 3 | 2010 | 107 | 0.410 |
Why?
|
| Confidence Intervals | 9 | 2014 | 237 | 0.410 |
Why?
|
| Osteoarthritis | 2 | 2008 | 146 | 0.410 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2018 | 50 | 0.400 |
Why?
|
| Consumer Product Safety | 1 | 2013 | 12 | 0.400 |
Why?
|
| Managed Care Programs | 2 | 2005 | 86 | 0.390 |
Why?
|
| Drug Approval | 1 | 2013 | 28 | 0.390 |
Why?
|
| Treatment Refusal | 6 | 2008 | 58 | 0.390 |
Why?
|
| Calcium Channel Blockers | 3 | 2023 | 59 | 0.390 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 489 | 0.380 |
Why?
|
| Postoperative Complications | 2 | 2017 | 1336 | 0.380 |
Why?
|
| Digestive System Diseases | 1 | 2013 | 14 | 0.380 |
Why?
|
| Decision Support Techniques | 2 | 2020 | 196 | 0.380 |
Why?
|
| Administration, Oral | 3 | 2023 | 371 | 0.380 |
Why?
|
| Resource Allocation | 1 | 2012 | 20 | 0.370 |
Why?
|
| Health Care Rationing | 1 | 2012 | 21 | 0.370 |
Why?
|
| Neoplasms | 3 | 2015 | 1378 | 0.370 |
Why?
|
| Ischemic Attack, Transient | 2 | 2019 | 96 | 0.360 |
Why?
|
| Social Justice | 1 | 2012 | 33 | 0.360 |
Why?
|
| Emergencies | 1 | 2013 | 124 | 0.360 |
Why?
|
| Disability Evaluation | 3 | 2019 | 216 | 0.360 |
Why?
|
| Life Expectancy | 1 | 2012 | 33 | 0.360 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2012 | 7 | 0.360 |
Why?
|
| Predictive Value of Tests | 8 | 2012 | 1117 | 0.350 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 932 | 0.350 |
Why?
|
| Coronary Disease | 2 | 2011 | 247 | 0.350 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 58 | 0.350 |
Why?
|
| Fractures, Bone | 2 | 2022 | 138 | 0.350 |
Why?
|
| Population Surveillance | 5 | 2017 | 210 | 0.350 |
Why?
|
| Cost of Illness | 3 | 2025 | 169 | 0.340 |
Why?
|
| Guidelines as Topic | 2 | 2010 | 159 | 0.340 |
Why?
|
| Ambulatory Care Facilities | 3 | 2012 | 104 | 0.340 |
Why?
|
| Drug Interactions | 6 | 2017 | 126 | 0.340 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 24 | 0.340 |
Why?
|
| Patients | 2 | 2020 | 117 | 0.340 |
Why?
|
| Home Nursing | 1 | 2011 | 21 | 0.330 |
Why?
|
| Electric Countershock | 3 | 2018 | 109 | 0.330 |
Why?
|
| Women | 1 | 2011 | 44 | 0.330 |
Why?
|
| Length of Stay | 7 | 2017 | 828 | 0.320 |
Why?
|
| Pragmatic Clinical Trials as Topic | 4 | 2024 | 37 | 0.320 |
Why?
|
| Legislation, Drug | 4 | 2017 | 22 | 0.320 |
Why?
|
| Hospitals | 2 | 2012 | 399 | 0.320 |
Why?
|
| Health Expenditures | 4 | 2021 | 122 | 0.310 |
Why?
|
| New England | 8 | 2014 | 271 | 0.310 |
Why?
|
| Clinical Protocols | 1 | 2011 | 138 | 0.310 |
Why?
|
| Mobility Limitation | 2 | 2020 | 49 | 0.310 |
Why?
|
| Hyperkalemia | 3 | 2022 | 20 | 0.310 |
Why?
|
| Acute Coronary Syndrome | 3 | 2017 | 254 | 0.300 |
Why?
|
| Psychotropic Drugs | 1 | 2010 | 81 | 0.300 |
Why?
|
| Physician-Nurse Relations | 1 | 2009 | 26 | 0.300 |
Why?
|
| Patient Compliance | 2 | 2012 | 370 | 0.300 |
Why?
|
| Cognitive Dissonance | 1 | 2009 | 5 | 0.300 |
Why?
|
| Self Care | 2 | 2009 | 218 | 0.290 |
Why?
|
| Attitude of Health Personnel | 5 | 2024 | 634 | 0.290 |
Why?
|
| Electronic Prescribing | 1 | 2009 | 11 | 0.290 |
Why?
|
| Ethics, Medical | 1 | 2009 | 40 | 0.290 |
Why?
|
| Conflict of Interest | 1 | 2009 | 38 | 0.290 |
Why?
|
| Abbreviations as Topic | 1 | 2008 | 2 | 0.290 |
Why?
|
| Communication Barriers | 1 | 2009 | 71 | 0.280 |
Why?
|
| Regression Analysis | 4 | 2016 | 498 | 0.280 |
Why?
|
| Insurance, Pharmaceutical Services | 4 | 2013 | 17 | 0.280 |
Why?
|
| Cognition Disorders | 3 | 2017 | 224 | 0.280 |
Why?
|
| Survivors | 3 | 2017 | 189 | 0.280 |
Why?
|
| Patient Care Management | 2 | 2020 | 30 | 0.270 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2008 | 11 | 0.270 |
Why?
|
| Medicare Part C | 2 | 2025 | 14 | 0.270 |
Why?
|
| Fees, Pharmaceutical | 2 | 2011 | 5 | 0.270 |
Why?
|
| Health Services | 2 | 2005 | 80 | 0.270 |
Why?
|
| Health Care Surveys | 5 | 2012 | 289 | 0.260 |
Why?
|
| Videotape Recording | 1 | 2007 | 46 | 0.260 |
Why?
|
| Assisted Living Facilities | 1 | 2007 | 12 | 0.260 |
Why?
|
| Longitudinal Studies | 9 | 2024 | 1294 | 0.260 |
Why?
|
| Financing, Personal | 4 | 2011 | 23 | 0.260 |
Why?
|
| Drug Evaluation | 2 | 2007 | 19 | 0.260 |
Why?
|
| Quality of Life | 5 | 2022 | 1266 | 0.260 |
Why?
|
| Physicians | 3 | 2018 | 488 | 0.260 |
Why?
|
| Focus Groups | 3 | 2025 | 329 | 0.260 |
Why?
|
| Cognition | 3 | 2022 | 515 | 0.260 |
Why?
|
| Consensus | 2 | 2025 | 175 | 0.250 |
Why?
|
| Attitude to Health | 2 | 2006 | 296 | 0.250 |
Why?
|
| Narration | 1 | 2007 | 54 | 0.250 |
Why?
|
| Health Services for the Aged | 2 | 2008 | 46 | 0.250 |
Why?
|
| Prescription Fees | 3 | 2014 | 5 | 0.250 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 143 | 0.250 |
Why?
|
| Hypoglycemic Agents | 2 | 2006 | 226 | 0.240 |
Why?
|
| Software | 4 | 2014 | 401 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 162 | 0.240 |
Why?
|
| Awards and Prizes | 1 | 2006 | 34 | 0.240 |
Why?
|
| International Normalized Ratio | 3 | 2012 | 36 | 0.240 |
Why?
|
| Tibial Arteries | 1 | 2006 | 1 | 0.240 |
Why?
|
| Health Care Costs | 2 | 2005 | 224 | 0.240 |
Why?
|
| Antirheumatic Agents | 3 | 2013 | 227 | 0.240 |
Why?
|
| Poisson Distribution | 3 | 2012 | 52 | 0.230 |
Why?
|
| Community Health Services | 2 | 2008 | 127 | 0.230 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2005 | 1 | 0.230 |
Why?
|
| Patient Care Team | 3 | 2025 | 338 | 0.230 |
Why?
|
| Correspondence as Topic | 1 | 2005 | 11 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 770 | 0.230 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 67 | 0.230 |
Why?
|
| Logistic Models | 10 | 2017 | 1274 | 0.230 |
Why?
|
| Religion | 1 | 2026 | 35 | 0.230 |
Why?
|
| Age Distribution | 5 | 2008 | 262 | 0.230 |
Why?
|
| Adolescent | 10 | 2017 | 6368 | 0.230 |
Why?
|
| Spirituality | 1 | 2026 | 44 | 0.230 |
Why?
|
| Mandatory Programs | 1 | 2005 | 17 | 0.230 |
Why?
|
| Physicians, Primary Care | 2 | 2017 | 79 | 0.220 |
Why?
|
| Population Dynamics | 1 | 2005 | 21 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2025 | 113 | 0.220 |
Why?
|
| Resilience, Psychological | 1 | 2026 | 67 | 0.220 |
Why?
|
| Mental Disorders | 1 | 2013 | 827 | 0.220 |
Why?
|
| Residential Facilities | 1 | 2004 | 19 | 0.220 |
Why?
|
| Inpatients | 2 | 2019 | 322 | 0.210 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 32 | 0.210 |
Why?
|
| Socioeconomic Factors | 10 | 2024 | 806 | 0.210 |
Why?
|
| Thrombolytic Therapy | 3 | 2003 | 205 | 0.210 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 66 | 0.210 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2004 | 28 | 0.210 |
Why?
|
| Quality Improvement | 2 | 2021 | 473 | 0.210 |
Why?
|
| Health Services Research | 4 | 2017 | 265 | 0.210 |
Why?
|
| Off-Label Use | 2 | 2015 | 14 | 0.210 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 532 | 0.200 |
Why?
|
| Young Adult | 7 | 2017 | 4883 | 0.200 |
Why?
|
| Diphosphonates | 1 | 2003 | 33 | 0.200 |
Why?
|
| Calcitonin | 1 | 2003 | 17 | 0.200 |
Why?
|
| Professional Role | 1 | 2024 | 45 | 0.200 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2003 | 47 | 0.200 |
Why?
|
| Child | 7 | 2011 | 4653 | 0.200 |
Why?
|
| Morbidity | 2 | 2020 | 110 | 0.200 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 80 | 0.190 |
Why?
|
| Group Practice | 1 | 2003 | 11 | 0.190 |
Why?
|
| Cost Sharing | 2 | 2021 | 15 | 0.190 |
Why?
|
| Statistics as Topic | 2 | 2014 | 147 | 0.190 |
Why?
|
| User-Computer Interface | 3 | 2009 | 127 | 0.190 |
Why?
|
| Risk | 3 | 2016 | 375 | 0.190 |
Why?
|
| Information Dissemination | 2 | 2015 | 114 | 0.190 |
Why?
|
| Data Collection | 4 | 2014 | 384 | 0.190 |
Why?
|
| Interviews as Topic | 3 | 2016 | 535 | 0.180 |
Why?
|
| Review Literature as Topic | 1 | 2002 | 41 | 0.180 |
Why?
|
| Models, Educational | 1 | 2002 | 68 | 0.180 |
Why?
|
| Paraproteinemias | 1 | 2022 | 16 | 0.180 |
Why?
|
| Nursing Staff | 2 | 2013 | 40 | 0.180 |
Why?
|
| Bias | 1 | 2002 | 117 | 0.180 |
Why?
|
| Prognosis | 9 | 2022 | 1793 | 0.180 |
Why?
|
| Social Norms | 1 | 2021 | 11 | 0.180 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 35 | 0.170 |
Why?
|
| Insurance, Health | 4 | 2009 | 153 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 65 | 0.170 |
Why?
|
| Pilot Projects | 4 | 2015 | 1030 | 0.170 |
Why?
|
| Edema | 1 | 2021 | 42 | 0.170 |
Why?
|
| Patient Transfer | 1 | 2002 | 93 | 0.170 |
Why?
|
| Publishing | 1 | 2002 | 95 | 0.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 54 | 0.160 |
Why?
|
| Survival Rate | 7 | 2019 | 849 | 0.160 |
Why?
|
| Pharmacy | 1 | 2021 | 17 | 0.160 |
Why?
|
| Weight Loss | 1 | 2023 | 276 | 0.160 |
Why?
|
| Sex Distribution | 4 | 2005 | 252 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 505 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2020 | 37 | 0.160 |
Why?
|
| Cardiac Catheterization | 3 | 2015 | 293 | 0.160 |
Why?
|
| Patient Safety | 2 | 2014 | 281 | 0.160 |
Why?
|
| Medicine | 1 | 2020 | 53 | 0.160 |
Why?
|
| Cause of Death | 4 | 2019 | 221 | 0.160 |
Why?
|
| Low Back Pain | 1 | 2021 | 113 | 0.160 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 22 | 0.160 |
Why?
|
| Venous Thromboembolism | 2 | 2014 | 154 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1148 | 0.150 |
Why?
|
| Empathy | 1 | 2020 | 69 | 0.150 |
Why?
|
| Medical Indigency | 3 | 2008 | 6 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2002 | 178 | 0.150 |
Why?
|
| Registries | 3 | 2017 | 935 | 0.150 |
Why?
|
| Sample Size | 2 | 2023 | 68 | 0.150 |
Why?
|
| Nurse's Role | 1 | 2020 | 132 | 0.150 |
Why?
|
| Health Services Accessibility | 3 | 2012 | 603 | 0.150 |
Why?
|
| Emergency Medical Services | 2 | 2016 | 264 | 0.150 |
Why?
|
| Chest Pain | 1 | 2020 | 86 | 0.150 |
Why?
|
| Observation | 1 | 2019 | 30 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 738 | 0.150 |
Why?
|
| Antidiuretic Agents | 1 | 2018 | 3 | 0.140 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2018 | 6 | 0.140 |
Why?
|
| Disease Management | 2 | 2019 | 235 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2019 | 85 | 0.140 |
Why?
|
| Anti-Anxiety Agents | 2 | 2010 | 31 | 0.140 |
Why?
|
| Internationality | 1 | 2018 | 46 | 0.140 |
Why?
|
| Delirium | 2 | 2016 | 55 | 0.140 |
Why?
|
| Anxiety | 2 | 2020 | 427 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 4 | 2012 | 197 | 0.140 |
Why?
|
| Thinness | 1 | 2018 | 44 | 0.140 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2009 | 26 | 0.140 |
Why?
|
| Health Facility Size | 2 | 2015 | 16 | 0.140 |
Why?
|
| Medication Adherence | 3 | 2022 | 202 | 0.140 |
Why?
|
| Education | 1 | 2018 | 66 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2019 | 165 | 0.140 |
Why?
|
| Child, Preschool | 4 | 2011 | 2090 | 0.130 |
Why?
|
| Pneumonia, Aspiration | 1 | 2017 | 15 | 0.130 |
Why?
|
| New York | 2 | 2016 | 144 | 0.130 |
Why?
|
| Cardiovascular Agents | 2 | 2011 | 107 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 349 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 1172 | 0.130 |
Why?
|
| Prescriptions | 1 | 2017 | 33 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 504 | 0.130 |
Why?
|
| Outpatients | 2 | 2017 | 143 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2018 | 74 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1235 | 0.130 |
Why?
|
| Organizational Innovation | 2 | 2008 | 85 | 0.130 |
Why?
|
| Propensity Score | 2 | 2015 | 192 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2008 | 45 | 0.120 |
Why?
|
| Third-Party Consent | 1 | 2016 | 9 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 375 | 0.120 |
Why?
|
| Behavior Control | 1 | 2016 | 15 | 0.120 |
Why?
|
| Kidney | 2 | 2016 | 460 | 0.120 |
Why?
|
| Insurance Claim Review | 3 | 2012 | 76 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2017 | 180 | 0.120 |
Why?
|
| Oxycodone | 1 | 2016 | 28 | 0.120 |
Why?
|
| Catheters, Indwelling | 1 | 2016 | 67 | 0.120 |
Why?
|
| Overweight | 1 | 2018 | 254 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2017 | 235 | 0.120 |
Why?
|
| Morphine | 1 | 2016 | 61 | 0.120 |
Why?
|
| Device Removal | 1 | 2016 | 64 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 106 | 0.120 |
Why?
|
| Depression | 3 | 2020 | 910 | 0.120 |
Why?
|
| Psychosocial Deprivation | 1 | 2015 | 8 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 859 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 47 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 56 | 0.120 |
Why?
|
| Residence Characteristics | 3 | 2008 | 230 | 0.120 |
Why?
|
| Fentanyl | 1 | 2016 | 67 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 2324 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 253 | 0.110 |
Why?
|
| Hospice Care | 1 | 2016 | 75 | 0.110 |
Why?
|
| Transitional Care | 1 | 2015 | 32 | 0.110 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 97 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2016 | 199 | 0.110 |
Why?
|
| Nausea | 1 | 2016 | 111 | 0.110 |
Why?
|
| Qualitative Research | 3 | 2025 | 763 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 1719 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 145 | 0.110 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 22 | 0.110 |
Why?
|
| Goals | 1 | 2015 | 96 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 3 | 2025 | 122 | 0.110 |
Why?
|
| Cross Infection | 1 | 2016 | 170 | 0.110 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 95 | 0.110 |
Why?
|
| Clinical Competence | 2 | 2024 | 731 | 0.110 |
Why?
|
| Heart Function Tests | 1 | 2014 | 17 | 0.110 |
Why?
|
| Pediatrics | 2 | 2008 | 265 | 0.110 |
Why?
|
| Organizational Culture | 2 | 2012 | 117 | 0.100 |
Why?
|
| Memory Disorders | 1 | 2014 | 53 | 0.100 |
Why?
|
| Hospital Mortality | 4 | 2016 | 881 | 0.100 |
Why?
|
| Consultants | 1 | 2014 | 12 | 0.100 |
Why?
|
| Urban Population | 1 | 2015 | 201 | 0.100 |
Why?
|
| Executive Function | 1 | 2014 | 71 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2016 | 157 | 0.100 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2013 | 15 | 0.100 |
Why?
|
| Contraindications | 2 | 2005 | 52 | 0.100 |
Why?
|
| Medical Staff | 1 | 2013 | 13 | 0.100 |
Why?
|
| Georgia | 3 | 2019 | 92 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 139 | 0.100 |
Why?
|
| Administrative Personnel | 1 | 2013 | 30 | 0.100 |
Why?
|
| Deductibles and Coinsurance | 2 | 2010 | 9 | 0.100 |
Why?
|
| History, Ancient | 1 | 2013 | 11 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 3 | 2018 | 162 | 0.100 |
Why?
|
| Insurance Coverage | 2 | 2011 | 98 | 0.090 |
Why?
|
| Pain Management | 1 | 2015 | 174 | 0.090 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 54 | 0.090 |
Why?
|
| Pharmacies | 1 | 2013 | 36 | 0.090 |
Why?
|
| Psychiatry | 1 | 2014 | 129 | 0.090 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2008 | 22 | 0.090 |
Why?
|
| Mammography | 2 | 2022 | 296 | 0.090 |
Why?
|
| Confidentiality | 1 | 2012 | 58 | 0.090 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 226 | 0.090 |
Why?
|
| Drug Storage | 1 | 2011 | 23 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2002 | 88 | 0.080 |
Why?
|
| Poverty | 2 | 2010 | 307 | 0.080 |
Why?
|
| Forecasting | 1 | 2011 | 231 | 0.080 |
Why?
|
| Anemia, Sickle Cell | 1 | 2011 | 65 | 0.080 |
Why?
|
| Internet | 1 | 2014 | 472 | 0.080 |
Why?
|
| Telephone | 1 | 2011 | 123 | 0.080 |
Why?
|
| Infant | 3 | 2011 | 1718 | 0.080 |
Why?
|
| Medical Records | 2 | 2008 | 140 | 0.080 |
Why?
|
| Seizures | 1 | 2011 | 141 | 0.080 |
Why?
|
| Educational Status | 1 | 2011 | 279 | 0.080 |
Why?
|
| Reference Values | 1 | 2010 | 330 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 462 | 0.070 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 161 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 31 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2007 | 606 | 0.070 |
Why?
|
| Medicare Part B | 2 | 2012 | 11 | 0.070 |
Why?
|
| Potassium | 2 | 2022 | 98 | 0.070 |
Why?
|
| Sampling Studies | 2 | 2012 | 65 | 0.070 |
Why?
|
| Medical Records, Problem-Oriented | 2 | 2021 | 13 | 0.070 |
Why?
|
| Information Services | 1 | 2008 | 35 | 0.070 |
Why?
|
| Antidepressive Agents | 2 | 2007 | 244 | 0.070 |
Why?
|
| Selection Bias | 2 | 2005 | 23 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 35 | 0.070 |
Why?
|
| Anecdotes as Topic | 1 | 2007 | 11 | 0.070 |
Why?
|
| Costs and Cost Analysis | 1 | 2008 | 106 | 0.070 |
Why?
|
| ROC Curve | 1 | 2008 | 295 | 0.070 |
Why?
|
| Tartrates | 1 | 2007 | 1 | 0.070 |
Why?
|
| Atenolol | 1 | 2007 | 9 | 0.070 |
Why?
|
| Propanolamines | 1 | 2007 | 10 | 0.070 |
Why?
|
| Carbazoles | 1 | 2007 | 13 | 0.060 |
Why?
|
| Task Performance and Analysis | 1 | 2008 | 130 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 2008 | 73 | 0.060 |
Why?
|
| Metoprolol | 1 | 2007 | 18 | 0.060 |
Why?
|
| Self Administration | 1 | 2007 | 51 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2024 | 102 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 230 | 0.060 |
Why?
|
| Needs Assessment | 2 | 2021 | 201 | 0.060 |
Why?
|
| Malpractice | 1 | 2006 | 20 | 0.060 |
Why?
|
| Medication Systems, Hospital | 1 | 2006 | 9 | 0.060 |
Why?
|
| Long QT Syndrome | 1 | 2006 | 31 | 0.060 |
Why?
|
| Ultrasonography, Doppler | 1 | 2006 | 29 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2006 | 28 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2007 | 214 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 198 | 0.060 |
Why?
|
| Video Recording | 1 | 2006 | 140 | 0.060 |
Why?
|
| Observer Variation | 1 | 2006 | 217 | 0.060 |
Why?
|
| Health Status | 3 | 2017 | 448 | 0.060 |
Why?
|
| Hospital Information Systems | 1 | 2005 | 10 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 67 | 0.050 |
Why?
|
| Joints | 1 | 2005 | 33 | 0.050 |
Why?
|
| Arthritis | 1 | 2005 | 53 | 0.050 |
Why?
|
| Muscular Diseases | 1 | 2005 | 51 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2007 | 284 | 0.050 |
Why?
|
| Geriatric Nursing | 1 | 2024 | 51 | 0.050 |
Why?
|
| Liability, Legal | 1 | 2004 | 17 | 0.050 |
Why?
|
| Acute Disease | 3 | 2014 | 665 | 0.050 |
Why?
|
| Vietnam | 1 | 2024 | 191 | 0.050 |
Why?
|
| Patient Care | 1 | 2004 | 79 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2026 | 278 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 290 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2006 | 502 | 0.050 |
Why?
|
| Resuscitation Orders | 1 | 2004 | 45 | 0.050 |
Why?
|
| Wrist Injuries | 1 | 2003 | 17 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2003 | 41 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2006 | 537 | 0.050 |
Why?
|
| Trust | 1 | 2004 | 82 | 0.050 |
Why?
|
| Liver Failure | 1 | 2003 | 18 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 420 | 0.050 |
Why?
|
| Health Surveys | 3 | 2013 | 319 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 50 | 0.050 |
Why?
|
| Self Concept | 2 | 2018 | 123 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 117 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2003 | 53 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2022 | 41 | 0.050 |
Why?
|
| Scotland | 1 | 2002 | 9 | 0.050 |
Why?
|
| Duodenal Ulcer | 1 | 2002 | 3 | 0.050 |
Why?
|
| Stomach Ulcer | 1 | 2002 | 8 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 171 | 0.050 |
Why?
|
| Alendronate | 1 | 2002 | 14 | 0.050 |
Why?
|
| Duodenal Diseases | 1 | 2002 | 14 | 0.050 |
Why?
|
| Consumer Behavior | 1 | 2002 | 38 | 0.050 |
Why?
|
| Random Allocation | 1 | 2002 | 200 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 2002 | 17 | 0.050 |
Why?
|
| Peptic Ulcer | 1 | 2002 | 18 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 85 | 0.040 |
Why?
|
| Prejudice | 1 | 2002 | 61 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 245 | 0.040 |
Why?
|
| Attitude | 1 | 2002 | 102 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2022 | 69 | 0.040 |
Why?
|
| Health Resources | 1 | 2002 | 92 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 2002 | 47 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 267 | 0.040 |
Why?
|
| Emotions | 1 | 2004 | 236 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2002 | 154 | 0.040 |
Why?
|
| Health Behavior | 1 | 2005 | 485 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 292 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 34 | 0.040 |
Why?
|
| Perception | 1 | 2022 | 187 | 0.040 |
Why?
|
| Reading | 1 | 2002 | 95 | 0.040 |
Why?
|
| Mass Screening | 2 | 2022 | 700 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 579 | 0.040 |
Why?
|
| Income | 2 | 2013 | 169 | 0.040 |
Why?
|
| Family Practice | 1 | 2002 | 214 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 296 | 0.040 |
Why?
|
| Women's Health | 1 | 2003 | 376 | 0.040 |
Why?
|
| Transferrins | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 30 | 0.040 |
Why?
|
| Systole | 2 | 2014 | 109 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 170 | 0.040 |
Why?
|
| Canada | 2 | 2014 | 157 | 0.040 |
Why?
|
| Transferrin | 1 | 2020 | 70 | 0.040 |
Why?
|
| Recurrence | 2 | 2014 | 665 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 332 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 46 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 136 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 327 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2018 | 11 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 78 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2020 | 134 | 0.040 |
Why?
|
| Competitive Medical Plans | 2 | 2009 | 2 | 0.040 |
Why?
|
| Monitoring, Physiologic | 2 | 2013 | 170 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2018 | 19 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 17 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2006 | 800 | 0.030 |
Why?
|
| Liver | 1 | 2003 | 875 | 0.030 |
Why?
|
| Specialization | 1 | 2018 | 82 | 0.030 |
Why?
|
| Psychometrics | 2 | 2012 | 396 | 0.030 |
Why?
|
| Walking | 1 | 2020 | 248 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2018 | 49 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 159 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 1229 | 0.030 |
Why?
|
| Journal Impact Factor | 1 | 2017 | 26 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 133 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 2401 | 0.030 |
Why?
|
| Patient Preference | 1 | 2017 | 87 | 0.030 |
Why?
|
| Oxymorphone | 1 | 2016 | 5 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 31 | 0.030 |
Why?
|
| Tramadol | 1 | 2016 | 14 | 0.030 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 33 | 0.030 |
Why?
|
| Rhabdomyolysis | 2 | 2007 | 23 | 0.030 |
Why?
|
| Echocardiography | 2 | 2014 | 513 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 374 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 78 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1503 | 0.030 |
Why?
|
| Heart Rate | 1 | 2018 | 335 | 0.030 |
Why?
|
| Rhode Island | 1 | 2016 | 110 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 120 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 222 | 0.030 |
Why?
|
| California | 2 | 2007 | 178 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 47 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 30 | 0.030 |
Why?
|
| Gait | 1 | 2016 | 124 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2007 | 554 | 0.030 |
Why?
|
| Economic Recession | 1 | 2014 | 5 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 268 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 15 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 79 | 0.030 |
Why?
|
| Analgesics | 1 | 2015 | 102 | 0.030 |
Why?
|
| Medicaid | 2 | 2009 | 379 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 309 | 0.030 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2013 | 2 | 0.030 |
Why?
|
| Creatinine | 1 | 2013 | 136 | 0.020 |
Why?
|
| Proteinuria | 1 | 2013 | 41 | 0.020 |
Why?
|
| Buprenorphine | 1 | 2016 | 199 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 86 | 0.020 |
Why?
|
| Health Facility Administrators | 1 | 2012 | 7 | 0.020 |
Why?
|
| Global Health | 1 | 2014 | 181 | 0.020 |
Why?
|
| Etanercept | 1 | 2012 | 33 | 0.020 |
Why?
|
| Adalimumab | 1 | 2012 | 30 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 420 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 64 | 0.020 |
Why?
|
| Infliximab | 1 | 2012 | 50 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2012 | 21 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 41 | 0.020 |
Why?
|
| Angioedema | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hypotension, Orthostatic | 1 | 2011 | 27 | 0.020 |
Why?
|
| Cost Savings | 1 | 2011 | 60 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2006 | 1439 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 472 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 183 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1165 | 0.020 |
Why?
|
| Health Care Sector | 1 | 2009 | 20 | 0.020 |
Why?
|
| Hospital Units | 1 | 2008 | 9 | 0.020 |
Why?
|
| Time | 1 | 2008 | 30 | 0.020 |
Why?
|
| Efficiency | 1 | 2008 | 39 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2013 | 423 | 0.020 |
Why?
|
| Safety | 1 | 2008 | 142 | 0.020 |
Why?
|
| Naproxen | 1 | 2007 | 6 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2008 | 106 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 12 | 0.020 |
Why?
|
| Lactones | 1 | 2007 | 16 | 0.020 |
Why?
|
| Sulfones | 1 | 2007 | 43 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 875 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 11 | 0.020 |
Why?
|
| Aluminum | 1 | 2007 | 13 | 0.020 |
Why?
|
| Program Development | 1 | 2008 | 208 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2007 | 88 | 0.020 |
Why?
|
| New Jersey | 1 | 2007 | 24 | 0.020 |
Why?
|
| Pyridines | 1 | 2007 | 120 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2007 | 135 | 0.020 |
Why?
|
| Informed Consent | 1 | 2007 | 142 | 0.020 |
Why?
|
| Amitriptyline | 1 | 2006 | 7 | 0.020 |
Why?
|
| Torsades de Pointes | 1 | 2006 | 6 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2006 | 95 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2005 | 45 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 81 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2004 | 36 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2004 | 104 | 0.010 |
Why?
|
| Resuscitation | 1 | 2004 | 67 | 0.010 |
Why?
|
| Chromans | 1 | 2003 | 16 | 0.010 |
Why?
|
| Sulfonylurea Compounds | 1 | 2003 | 12 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 45 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2004 | 173 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 993 | 0.010 |
Why?
|
| Metformin | 1 | 2003 | 77 | 0.010 |
Why?
|
| Exercise Test | 1 | 2003 | 257 | 0.010 |
Why?
|
| Aspirin | 1 | 2003 | 172 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 183 | 0.010 |
Why?
|
| Physician's Role | 1 | 2002 | 122 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 809 | 0.010 |
Why?
|
| Insulin | 1 | 2003 | 697 | 0.010 |
Why?
|